

DEFINITIONS

In this document, unless the context otherwise requires, the following terms and expressions have the meanings set forth below. Certain other terms are explained in the section headed “Glossary of Technical Terms” in this document.

“Accountant’s Report”	the accountant’s report of our Company for the Track Record Period prepared by PricewaterhouseCoopers, the text of which is set out in Appendix I to this document
“affiliate(s)”	with respect to any specified person, any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
“AFRC”	the Accounting and Financial Reporting Council of Hong Kong
“Articles” or “Articles of Association”	the articles of association of our Company, conditionally adopted on September 20, 2025 with effect upon the [REDACTED] (as amended, supplemented or otherwise modified from time to time), a summary of which is set out in Appendix IV to this document
“Audit Committee”	the audit committee of our Board
“Board” or “Board of Directors”	the board of Directors
“Business Day” or “business day”	a day on which banks in Hong Kong are generally open for normal business to the public and which is not a Saturday, Sunday or public holiday in Hong Kong
“CAGR”	compound annual growth rate
“Capital Market Intermediaries”	the capital market intermediaries as named in the section headed “Directors and Parties Involved in the [REDACTED]” in this document
“[REDACTED]”	[REDACTED]
“CCB Investment”	CCB Investment (Kunshan) Venture Capital Enterprise (Limited Partnership)* (建創中民(昆山)創業投資企業(有限合夥)), a limited partnership established in the PRC with limited liability on October 17, 2017 and one of our [REDACTED] Investors
“Changjiang Innovation”	Changjiang Securities Innovation Investment (Hubei) Co., Ltd.* (長江證券創新投資(湖北)有限公司), a limited liability company established in the PRC on December 22, 2016 and one of our [REDACTED] Investors

DEFINITIONS

“China” or “the PRC”	the People’s Republic of China, which only in the context of describing PRC rules, laws, regulations, regulatory authority, and any PRC entities or citizens under such rules, laws and regulations and other legal or tax matters in this document, excludes Taiwan, Hong Kong and the Macau Special Administrative Region of the PRC
“China Anti-Cancer Association”	China Anti-Cancer Association (中國抗癌協會)
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“Company”, “our Company”, “the Company”	Wuhan Ammunition Life-tech Co., Ltd.* (武漢艾米森生命科技股份有限公司), formerly known as Wuhan Ammunition Life-tech Company Limited (武漢艾米森生命科技有限公司), a limited liability company established in the PRC on January 28, 2015 which was converted into a joint stock company with limited liability on July 28, 2025
“Company Law” or “PRC Company Law”	Company Law of the People’s Republic of China (中華人民共和國公司法), as amended, supplemented or otherwise modified from time to time
“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“connected transaction(s)”	has the meaning ascribed to it under the Listing Rules
“Controlling Shareholder(s)”	has the meaning ascribed to it under the Listing Rules and unless the context otherwise requires, refers to Dr. Zhang, Wuhan Changsheng, Wuhan Aiminisen and Wuhan Weiai, details of which are set forth in the section headed “Relationship with Our Controlling Shareholders”
“Core Products”	has the meaning ascribed thereto in Chapter 18A of the Listing Rules and are the products for the purpose of satisfying the eligibility requirements under Chapter 18A; for the purpose of this document, our Core Products refer to IHepcomf (艾馨甘) and IUriSure (艾光樂)
“CSRC”	China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)”	the director(s) of our Company

DEFINITIONS

“Dongke Chuangxing”	Wuhan Dongke Chuangxing Enterprise Business Consulting Partnership (Limited Partnership)* (武漢東科創星企業商務諮詢合夥企業(有限合夥)), formerly known as Wuhan Dongke Chuangxing Angel Investment Center (Limited Partnership) (武漢東科創星天使投資中心(有限合夥)), a limited partnership established in the PRC on July 11, 2014 and one of our [REDACTED] Investors
“Dr. Dong”	Dr. Dong Lanlan (董蘭蘭), our executive Director
“Dr. Zhang”	Dr. Zhang Lianglu (張良祿), our founder, a Controlling Shareholder, the chairman of our Board, an executive Director and the general manager
“EIT”	enterprise income tax
“EIT Law”	Enterprise Income Tax Law of the People’s Republic of China (中華人民共和國企業所得稅法), as amended, supplemented or otherwise modified from time to time
“Employee Incentive Scheme(s)”	employee equity incentive schemes of our Company which was adopted on August 26, 2025 and December 18, 2025, respectively, a summary of the principal terms of each scheme is set forth in the paragraph headed “Appendix V – Statutory and General Information – D. Employee Incentive Schemes” in this document
“EU”	European Union
“Extreme Conditions”	the occurrence of “extreme conditions” as announced by any government authority of Hong Kong due to a super typhoon or other natural disaster of a substantial scale seriously affects the working public’s ability to resume work or brings safety concern for a prolonged period
“FDA”	the Food and Drug Administration of the U.S.
“[REDACTED]”	[REDACTED]
“Frost & Sullivan” or “Industry Consultant”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., our industry consultant
“Frost & Sullivan Report”	the industry report commissioned by our Company and independently prepared by Frost & Sullivan, a summary of which is set forth in the section headed “Industry Overview” in this document

DEFINITIONS

“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“GMP”	Good Manufacturing Practice
“Group”, “our Group”, “we”, “us” or “our”	the Company and its subsidiaries, or any one of them as the context may require or, where the context refers to any time prior to its incorporation, the business which its predecessors or the predecessors of its present subsidiaries, or any one of them as the context may require, were or was engaged in and which were subsequently assumed by it
“Guide”	the Guide for New Listing Applicants, as published by the Stock Exchange on November 29, 2023 and made effective on January 1, 2024, as amended or supplemented or otherwise modified from time to time
“H Share(s)”	overseas listed foreign shares in the share capital of our Company with nominal value of RMB0.1 each, which are to be subscribed for and [REDACTED] in HK dollars and are to be [REDACTED] on the Hong Kong Stock Exchange
“[REDACTED]”	[REDACTED]
“Heying Tongsheng”	Heying Tongsheng (Wuhan) Enterprise Management Center (Limited Partnership)* (禾盈同晟(武漢)企業管理中心(有限合夥)), a limited partnership established in the PRC with limited liability on June 16, 2017 and one of our [REDACTED] Investors
“HK\$” or “HK dollars”	Hong Kong dollars and cents, respectively, the lawful currency of Hong Kong
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]

DEFINITIONS

“[REDACTED]” [REDACTED]

“[REDACTED]” [REDACTED]

“[REDACTED]” [REDACTED]

“Hong Kong” or “HK” the Hong Kong Special Administrative Region of the PRC

“Hong Kong Listing Rules” or “Listing Rules” the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (as amended from time to time)

“[REDACTED]” [REDACTED]

“[REDACTED]” [REDACTED]

“Hong Kong Stock Exchange” or “Stock Exchange” The Stock Exchange of Hong Kong Limited, a wholly owned subsidiary of Hong Kong Exchanges and Clearing Limited

“[REDACTED]” [REDACTED]

“[REDACTED]” [REDACTED]

“Hubei MPA” Hubei Medical Products Administration (湖北省藥品監督管理局)

DEFINITIONS

“Hybribio Biotech”	Guangzhou Hybribio Biotech Co., Ltd.* (廣州凱普生物科技有限公司), a limited liability company established in the PRC on April 6, 2012 and one of our [REDACTED] Investors
“IASB”	International Accounting Standards Board
“IFRS”	International Financial Reporting Standards, which include standards, amendments and interpretations promulgated by the International Accounting Standards Board and the International Accounting Standards and interpretation issued by the International Accounting Standards Committee
“iKang (愛康國賓)”	iKang Healthcare Group, Inc. (愛康國賓健康體檢管理集團有限公司) a limited company established in the PRC on September 13, 2004
“Independent Third Party(ies)”	any entity or person who to the best of our Directors’ knowledge, information and belief, is not a connected person of our Company within the meaning ascribed thereto under the Listing Rules
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“IP Legal Advisors”	AllBright Law Offices, the legal advisors of our Company as to intellectual property law in PRC

DEFINITIONS

“IRB”	institutional review board
“Jiaxing Danlu”	Jiaxing Danlu Equity Investment Partnership Enterprise (Limited Partnership)* (嘉興丹麓股權投資合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on December 22, 2025 and one of our [REDACTED] Investors
“Jinjiang Xuanhong”	Jinjiang Xuanhong No. 10 Equity Investment Partnership (Limited Partnership)* (晉江軒弘十號股權投資合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on June 10, 2022 and one of our [REDACTED] Investors
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“Joint Sponsors” and “[REDACTED]”	the joint sponsors and the [REDACTED] of the [REDACTED] of the H Shares on the Hong Kong Stock Exchange as named in the section headed “Directors and Parties Involved in the [REDACTED]” in this document
“KingMed Medical (金域醫學)”	Guangzhou KingMed Medical Laboratory Group Co., Ltd. (廣州金域醫學檢驗集團股份有限公司) a limited company established in the PRC on May 26, 2006
“Latest Practicable Date”	April 1, 2026, being the latest practicable date for the purpose of ascertaining certain information contained in this document prior to its publication
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]

DEFINITIONS

“Main Board”	the stock market (excluding the option market) operated by the Hong Kong Stock Exchange which is independent from and operated in parallel with the Growth Enterprise Market of the Hong Kong Stock Exchange
“Ministry of Finance” or “MOF”	Ministry of Finance of the PRC (中華人民共和國財政部)
“MOFCOM”	Ministry of Commerce of the PRC (中華人民共和國商務部)
“NCCN”	National Comprehensive Cancer Network (美國國家綜合癌症網絡)
“NDRC”	the National Development and Reform Commission of the PRC (中華人民共和國國家發展和改革委員會)
“NSFC”	National Natural Science Foundation of China (國家自然科學基金委員會)
“NHFPC”	National Health and Family Planning Commission, now known as National Health Commission of the PRC (中華人民共和國國家衛生和計劃生育委員會)
“Nomination Committee”	the nomination committee of our Board
“NMPA”	National Medical Products Administration (國家藥品監督管理局), formerly known as China Food and Drug Administration (“CFDA”) (國家食品藥品監督管理局) or China Drug Administration (“CDA”) (國家藥品監督管理局); references to NMPA include CFDA and CDA
“NPC”	the National People’s Congress of the PRC (中華人民共和國全國人民代表大會)
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]

DEFINITIONS

“[REDACTED]”	[REDACTED]
“Overseas Listing Trial Measures”	the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) promulgated by the CSRC on February 17, 2023
“PBOC”	the People’s Bank of China (中國人民銀行), the central bank of the PRC
“PRC Company Law”	the Company Law of the People’s Republic of China (《中華人民共和國公司法》)
“PRC GAAP”	generally accepted accounting principles of PRC
“PRC Legal Advisors”	Jingtian & Gongcheng, the legal advisors of our Company as to the PRC laws
“PRC Securities Law”	the Securities Law of the PRC (《中華人民共和國證券法》), as amended, supplemented or otherwise modified from time to time
“[REDACTED] Investment(s)”	the investment(s) in our Company undertaken by the [REDACTED] Investors pursuant to the relevant equity transfer agreement(s) and/or capital increase agreement(s) prior to the [REDACTED], details of which are set out in the section headed “History, Development and Corporate Structure” in this document
“[REDACTED] Investor(s)”	the investor(s) who participated in our [REDACTED] Investments, details of which are set out in the section headed “History, Development and Corporate Structure” in this document
“[REDACTED]”	[REDACTED]

DEFINITIONS

“[REDACTED]”	[REDACTED]
“R&D”	research and development
“Regulation S”	Regulation S under the U.S. Securities Act
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“SAFE”	the State Administration of Foreign Exchange of the PRC (中華人民共和國外匯管理局)
“SAIC”	the State Administration for Industry and Commerce of the PRC (中華人民共和國國家工商行政管理總局), currently known as SAMR
“SAMR”	the State Administration for Market Regulation (國家市場監督管理總局)
“Securities Law”	the Securities Law of the PRC (中華人民共和國證券法), as amended, supplemented or otherwise modified from time to time
“SFC”	the Securities and Futures Commission of Hong Kong
“SFO”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time
“STA”	the State Taxation Administration of the PRC (中華人民共和國國家稅務總局)
“Shanghai Jianteng”	Shanghai Jianteng Enterprise Management Partnership (Limited Partnership)* (上海建騰企業管理合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on October 27, 2017 and one of our [REDACTED] Investors
“Share(s)”	ordinary share(s) in the share capital of our Company with a nominal value of RMB0.1 each upon the completion of the Share Subdivision; before the completion of the Share Subdivision, ordinary share(s) in the share capital of our Company with a nominal value of RMB1.0 each
“Share Subdivision”	the sub-division of the Shares by the Company where the Company subdivided its Share from one Share of RMB1.0 each into ten Shares of RMB0.1 each, which will become effective immediately prior to the [REDACTED]
“Shareholder(s)”	holder(s) of our Share(s)

DEFINITIONS

“Sophisticated Investor(s)”	has the meaning ascribed to it under Chapter 2.3 of the Guide
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“State Council”	the State Council of the PRC (中華人民共和國國務院)
“subsidiary(ies)”	has the meaning ascribed thereto under the Listing Rules
“Suzhou Kinghall”	Suzhou Kinghall Phase II Equity Investment Partnership (Limited Partnership)* (蘇州金闔二期股權投資合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on April 3, 2020 and one of our [REDACTED] Investors
“Takeovers Code”	the Codes on Takeovers and Mergers and Share Buy-backs issued by the SFC, as amended, supplemented or otherwise modified from time to time
“Track Record Period”	the years ended December 31, 2024 and 2025
“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“United States” or “U.S.”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“[REDACTED] Share(s)”	ordinary share(s) in the share capital of our Company, with a nominal value of RMB0.1 each (taking into account the Share Subdivision), which is/are not [REDACTED] or [REDACTED] on any stock exchange
“U.S. dollars”, “US\$” or “USD”	United States dollars, the lawful currency of the United States
“USPTO”	the United States Patent and Trademark Office
“U.S. Securities Act”	the U.S. Securities Act of 1933, as amended, supplemented or otherwise modified from time to time, and the rules and regulations promulgated thereunder

DEFINITIONS

“[REDACTED]”	[REDACTED]
“[REDACTED]”	[REDACTED]
“Wuhan Aiminisen”	Wuhan Aiminisen Medical Consulting Services Partnership (Limited Partnership)* (武漢艾米尼森醫療諮詢服務合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on December 22, 2020, one of our Controlling Shareholders
“Wuhan Aiminisen Biopharma”	Wuhan Aiminisen Biopharmaceutical Co., Ltd.* (武漢艾米尼森生物醫藥有限責任公司), a limited liability company established in the PRC on September 9, 2014 which was subsequently deregistered on July 1, 2020
“Wuhan Changsheng”	Wuhan Changsheng Medical Consulting Services Partnership (Limited Partnership)* (武漢昶晟醫療諮詢服務合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on March 29, 2022, one of our Controlling Shareholders
“Wuhan High-tech”	Wuhan High-tech Medical Equipment Park Co., Ltd.* (武漢高科醫療器械企業孵化有限公司), a limited liability company established in the PRC on December 28, 2011 and one of our [REDACTED] Investors
“Wuhan Optics Valley”	Wuhan Optics Valley Talent Venture Capital Partnership (Limited Partnership)* (武漢光谷人才創業投資合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on August 20, 2015 and one of our [REDACTED] Investors
“Wuhan Weiai”	Wuhan Weiai Fangxing Medical Consulting Services Partnership (Limited Partnership)* (武漢未艾方興醫療諮詢服務合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on September 20, 2019, one of our Controlling Shareholders
“VAT”	value-added tax; all amounts are exclusive of VAT in this document except where indicated otherwise
“Xuanpan No. 1”	Sanya Xuanpan No. 1 Equity Investment Fund Partnership (Limited Partnership)* (三亞軒盼一號股權投資基金合夥企業(有限合夥)), a limited partnership established in the PRC with limited liability on August 24, 2021 and one of our [REDACTED] Investors
“%”	per cent

DEFINITIONS

In this document, the terms “associate”, “close associate”, “core connected person” and “substantial shareholder” shall have the meanings given to such terms in the Hong Kong Listing Rules, unless the context otherwise requires.

Certain amounts and percentage figures included in this document have been subject to rounding. Accordingly, figures shown as totals in certain tables may not be an arithmetic aggregation of the figures preceding them. Any discrepancies in any table or chart between the total shown and the sum of the amounts listed are due to rounding.

For ease of reference, the names of the PRC established companies or entities, laws or regulations have been included in this document in both the Chinese and English languages and in the event of any inconsistency, the Chinese versions shall prevail.